


ALLEVYN<sup>®</sup> LIFE Foam Dressing plus standard of care (SOC) significantly reduced the incidence of sacral hospital-acquired pressure injuries (HAPIs) and is cost-saving when compared with SOC alone

## Overview



- An open-label, parallel group, multicentre, randomised controlled trial conducted in 22 medical, surgical and intensive care units at 12 hospitals in Italy, designed to assess if ALLEVYN LIFE Dressing can help prevent sacral pressure injuries (PIs)<sup>1</sup>
- Patients at risk of sacral PIs (Braden Scale Score  $\leq 16$ ) were randomised to the following treatment groups:<sup>1</sup>
  - ALLEVYN LIFE Dressing + SOC (n=351)
  - SOC (n=358)
- SOC included PI risk assessment, skin assessment three times daily, routine positioning every 4 hours, use of an active support surface as appropriate and incontinence skin care<sup>1</sup>
- A health economic analysis was retrospectively performed on the results on the randomised controlled trial data to determine the cost-effectiveness of ALLEVYN LIFE Dressing<sup>2</sup>

## Methodology




## Results

With ALLEVYN LIFE Dressing + SOC, versus SOC alone:<sup>1</sup>



Use of ALLEVYN LIFE Dressing plus SOC is cost-saving versus SOC alone\*<sup>2</sup>



## Conclusion

Use of ALLEVYN LIFE Dressing in addition to standard of care significantly reduced the incidence of sacral pressure injuries in at-risk patients in medical and surgical units compared with standard of care alone. Additionally, use of ALLEVYN LIFE Dressing in combination with standard of care was shown to be cost-saving versus standard of care alone.

\*Cost estimates for treating stage I and stage II HAPIs from an Italian perspective were estimated to be €4,610 and €6,629, respectively. In a cohort of 1,000 patients, the ALLEVYN LIFE Dressing plus standard care would result in 80 fewer HAPIs versus standard care alone, saving €179 per patient

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

**References:** 1. Forni C, Gaziano D, Allegrini E, et al. *Int J Nurs Stud.* 2022;127:104172. 2. Mezzalana E, Ambrosi E, Askew N, et al. *Int J Health Policy Manag.* 2024. Published online Nov 10, 2024. doi:10.34172/ijhpm.8371.